about
Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxinMucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccineAnthrax vaccination strategiesChemical synthesis and immunological properties of oligosaccharides derived from the vegetative cell wall of Bacillus anthracisGenetic vaccines for anthrax based on recombinant adeno-associated virus vectorsNew developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entitiesAntigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine.Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthraxProtective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection.Improvement of a potential anthrax therapeutic by computational protein design.Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA humanTrimethyl Chitosan Nanoparticles Encapsulated Protective Antigen Protects the Mice Against Anthrax.
P2860
Q24796044-0B6AD947-7112-47F2-8246-E7C3CBA82091Q28387065-B31962D8-3B71-4FDA-A5CC-AB9679839986Q28392248-574F4632-62CA-41E3-9A1C-21ABAF6C2DC4Q28394012-E2ED42BB-2501-4BC0-BAB4-87FB647F4993Q33713243-3EF674FF-94C8-4AEA-AD6B-E155CE2EF398Q34066161-AFC39F13-DE30-4681-A0FD-0E9C9B1A8935Q34241550-7B7C0ECB-9C4A-41A8-95C1-C622E51C2E38Q35783845-54B7EEF5-7A88-4609-A987-DEAC37C8D890Q36478354-E75A6931-649F-48F9-97BE-179257C344D6Q36668524-7116DFA2-9F4C-4430-8C89-C44B0906AAF1Q37530303-FD84C34D-9735-4C31-8A40-9580A9D1B2D3Q38421933-7CA15D58-E6BF-473E-AEEF-7BD42070F25FQ39143157-718700D9-3BC1-4D6A-956D-B410091AB294Q42217708-CC53AE9E-03E6-481A-9AA4-071413455D69Q52608524-23552363-9F4A-4B4C-9250-DA454F85B3AC
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականին հրատարակուած գիտական յօդուած
@hyw
2002 թվականին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
type
altLabel
The Anthrax Vaccine
@en
P356
P1433
P1476
The Anthrax Vaccine
@en
P356
10.17226/10310
P407
P577
2002-01-01T00:00:00Z